Quarterly ResultMay 11, 2026, 04:57 PM
Biomea Fusion Advances Diabetes & Obesity Trials; Q1 Net Loss $12.4M
AI Summary
Biomea Fusion successfully completed chronic toxicology studies for icovamenib, supporting its advancement to chronic clinical dosing. The company reported topline 52-week data from the Phase II COVALENT-112 trial in T1D, showing a 52% increase in C-peptide AUC at Week 12, and initiated two Phase II trials for icovamenib in T2D. The Phase I GLP-131 obesity trial is on track for initial 28-day weight reduction data in Q2 2026. For Q1 2026, Biomea reported a net loss of $12.4 million, a significant reduction from $29.3 million in Q1 2025, with R&D and G&A expenses also decreasing. The company projects a cash runway into Q1 2027.
Key Highlights
- Icovamenib chronic toxicology studies completed, supporting chronic clinical dosing.
- Phase II COVALENT-112 (T1D) showed 52% C-peptide AUC increase at Week 12 (200 mg group).
- Phase II COVALENT-211 & -212 (T2D) initiated; topline 26-week data expected Q4 2026.
- Phase I GLP-131 (BMF-650) obesity trial initial 28-day weight data expected Q2 2026.
- Q1 2026 net loss was $12.4 million, a decrease from $29.3 million in Q1 2025.
- R&D expenses decreased to $9.1 million in Q1 2026 from $22.9 million in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $45.1 million as of March 31, 2026.
- Cash runway projected into the first quarter of 2027.